Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Reducing CAR-T toxicity

Yu-Tzu Tai • 15 Sep 2019
IMW 2019
Multiple Myeloma CAR-T

Dr. Yu-Tzu Tai, PhD of the Dana-Farber Cancer Institute, Boston, MA describes how CAR-T cells may be used to reduce the toxic effects of therapy and the promise of new antibody-drug conjugates. Recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

More from Yu-Tzu Tai

Using γ-secretase inhibitors to potentiate the efficacy of BCMA-targeted therapy in multiple myeloma 3:28
Using γ-secretase inhibitors to potentiate the efficacy of BCMA-targeted therapy in multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
Novel target antigens to improve the efficacy of immunotherapeutics in multiple myeloma 5:22
Novel target antigens to improve the efficacy of immunotherapeutics in multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
Rationale for using immunotherapies in the frontline treatment of multiple myeloma 1:35
Rationale for using immunotherapies in the frontline treatment of multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
BiTEs for MM 2:58
BiTEs for MM
Yu-Tzu Tai • 15 Sep 2019

Related Videos

Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals